119 related articles for article (PubMed ID: 3138819)
1. Studies on the procurement of blood coagulation factor VIII. In vitro studies on blood components prepared in half-strength citrate anticoagulant 18 hours after phlebotomy.
Griffin B; Bell K; Prowse C
Vox Sang; 1988; 55(1):9-13. PubMed ID: 3138819
[TBL] [Abstract][Full Text] [Related]
2. Studies on the procurement of blood coagulation factor VIII in vitro studies on blood components prepared in half-strength citrate anticoagulant.
Prowse C; Waterston YG; Dawes J; Farrugia A
Vox Sang; 1987; 52(4):257-64. PubMed ID: 3114954
[TBL] [Abstract][Full Text] [Related]
3. Red cell and platelet concentrates from blood collected into half-strength citrate anticoagulant: improved maintenance of red cell 2,3-diphosphoglycerate in half-citrate red cells.
Farrugia A; Douglas S; James J; Whyte G
Vox Sang; 1992; 63(1):31-8. PubMed ID: 1413661
[TBL] [Abstract][Full Text] [Related]
4. Studies on the procurement of blood coagulation factor VIII. In vivo studies on blood components prepared in half-strength citrate anticoagulant.
Griffin B; Bell K; Prowse C
Vox Sang; 1988; 54(4):193-8. PubMed ID: 3133879
[TBL] [Abstract][Full Text] [Related]
5. In vitro properties of red cells prepared from half-strength citrate CPD/RAS-2 (Erythro-sol) donations in PL-146 plastic.
Hornsey VS; MacDonald S; Drummond O; Bethel H; Walker B; Prowse CV
Transfus Med; 2000 Mar; 10(1):31-5. PubMed ID: 10760201
[TBL] [Abstract][Full Text] [Related]
6. Stability of blood coagulation factors and inhibitors in blood drawn into half-strength citrate anticoagulant.
Suontaka AM; Akerblom O; Blombäck M; Eriksson L; Högman CF; Payrat JM
Vox Sang; 1996; 71(2):97-102. PubMed ID: 8873419
[TBL] [Abstract][Full Text] [Related]
7. Characterization of blood components separated from donated whole blood after an overnight holding at room temperature with the buffy coat method.
Lu FQ; Kang W; Peng Y; Wang WM
Transfusion; 2011 Oct; 51(10):2199-207. PubMed ID: 21492181
[TBL] [Abstract][Full Text] [Related]
8. Blood components in the treatment of acute blood loss: use of freeze-preserved red cells, platelets, and plasma proteins.
Valeri CR
Anesth Analg; 1975; 54(1):1-14. PubMed ID: 1090205
[TBL] [Abstract][Full Text] [Related]
9. Contributions to the optimal use of human blood. VIII. Stability of blood coagulation factor VII during collection and storage of whole blood and plasma.
Vermeer C; Soute BA; Ates G; Hellings JA; Brummelhuis HG
Vox Sang; 1976; 31(1 SUPPL):55-67. PubMed ID: 12616
[TBL] [Abstract][Full Text] [Related]
10. Effect of plasma freezing temperature, anticoagulant and time of storage on factor VIII:C activity in cryoprecipitate.
Piedras J; Sánchez-Montero PE; Herrera FM; Córdova MS; Sánchez-Medal L
Arch Med Res; 1993; 24(1):23-6. PubMed ID: 8292873
[TBL] [Abstract][Full Text] [Related]
11. Survival and biochemical characteristics of stored red cells preserved with citrate-phosphate-dextrose-adenine-one and two and prepared from whole blood maintained at 20 to 24 degrees C for eight hours following phlebotomy.
Moroff G; Morse EE; Katz AJ; Kahn RA; Dende D; Swatman L; Staggs SD
Transfusion; 1984; 24(2):115-9. PubMed ID: 6710583
[TBL] [Abstract][Full Text] [Related]
12. In vitro effect on stored red blood cells and platelets after a 15-hour delayed refrigeration of whole blood prior to component preparation in CPD-AD.
Koerner K; Sahlmen P; Stampe D
Vox Sang; 1986; 50(3):141-5. PubMed ID: 3716287
[TBL] [Abstract][Full Text] [Related]
13. Overnight storage of whole blood: a comparison of two designs of butane-1,4-diol cooling plates.
van der Meer PF; Pietersz RN
Transfusion; 2007 Nov; 47(11):2038-43. PubMed ID: 17958532
[TBL] [Abstract][Full Text] [Related]
14. Characterization of factors affecting the stability of frozen heparinized plasma.
Palmer DS; Rosborough D; Perkins H; Bolton T; Rock G; Ganz PR
Vox Sang; 1993; 65(4):258-70. PubMed ID: 8310678
[TBL] [Abstract][Full Text] [Related]
15. The bioequivalence of frozen plasma prepared from whole blood held overnight at room temperature compared to fresh-frozen plasma prepared within eight hours of collection.
Dumont LJ; Cancelas JA; Maes LA; Rugg N; Whitley P; Herschel L; Siegel AH; Szczepiorkowski ZM; Hess JR; Zia M
Transfusion; 2015 Mar; 55(3):476-84. PubMed ID: 25233805
[TBL] [Abstract][Full Text] [Related]
16. A clinical trial of red-cell concentrate prepared from blood collected in half-strength citrate anticoagulant.
Murphy WG; Palmer JB; Wilson R; Prowse CV; McClelland DB
Transfus Med; 1991 Mar; 1(1):25-9. PubMed ID: 9259823
[TBL] [Abstract][Full Text] [Related]
17. Effect of delayed refrigeration on plasma factors in whole blood collected in CPDA-2.
Sohmer PR; Bolin RB; Scott RL; Smith DJ
Transfusion; 1982; 22(6):488-90. PubMed ID: 6815841
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the overnight hold of whole blood at room temperature, before component processing: platelets (PLTs) from PLT-rich plasma.
van der Meer PF; Cancelas JA; Vassallo RR; Rugg N; Einarson M; Hess JR;
Transfusion; 2011 Jan; 51 Suppl 1():45S-49S. PubMed ID: 21223295
[TBL] [Abstract][Full Text] [Related]
19. Contribution to the optimal use of human blood. VII. Increase of the yield of factor VIII in four-donor cryoprecipitate by an improved processing of blood and plasma.
Vermeer C; Soute BA; Ates G; Brummelhuis HG
Vox Sang; 1976; 30(1):1-22. PubMed ID: 1251567
[TBL] [Abstract][Full Text] [Related]
20. Plasma and cryoprecipitate manufactured from whole blood held overnight at room temperature meet quality standards.
Serrano K; Scammell K; Weiss S; Culibrk B; Levin E; Gyöngyössy-Issa M; Devine DV
Transfusion; 2010 Feb; 50(2):344-53. PubMed ID: 19843287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
